FDA Accepts Supplement for Doxorubicin Hydrochloride by Qilu Pharma
The FDA has accepted a supplemental application (ANDA219881) for Doxorubicin Hydrochloride submitted by Qilu Pharma, with a standard review priority.
Company
Pharmaceutical intelligence for Qilu Pharma with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.